GlyCare™ 3FL

One of the most abundant fucosylated HMO

GlyCare™ 3-Fucosyllactose Overview

3FL (3-Fucosyllactose) is a highly abundant, α1-3 fucosylated HMO in human milk.  GlyCare™ 3FL is presently undergoing development.

Immunity and Infections

Clinical studies suggest a relationship between HMOs and some immune outcomes in infants.  Emerging science suggest that specific HMOs at the correct level of supplementation may help to reduce the risk of certain infections in infants consuming infant formula and in infants who are breastfed.

Emerging evidence from preclinical studies suggest that 3’FL may support immune health via inhibiting the adhesion of pathogens to the intestinal wall (1,2).

Gut Health and Microbiota

Clinical and preclinical studies report that HMOs may help to stimulate the growth of beneficial bacteria, which are believed to be important for development of the microbiota and gut health. Evidence from preclinical studies suggests 3’FL may have a role in gut health via its positive impact on the growth of bifidobacteria which are considered to be beneficial for gut health (3,4,5).

References

1. Weichert, S., Jennewein, S., Hüfner, E., Weiss, C., Borkowski, J., Putze, J., & Schroten, H. (2013). Bioengineered 2’-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutrition Research, 33(10), 831–838. https://doi.org/10.1016/j.nutres.2013.07.009 

2. Brassart, D., Woltz, A., Golliard, M., & Neeser, J. R. (1991). In vitro inhibition of adhesion of Candida albicans clinical isolates to human buccal epithelial cells by Fucα1→2Galβ-bearing complex carbohydrates. Infection and Immunity, 59(5), 1605–1613. https://doi.org/10.1128/iai.59.5.1605-1613.1991 

3. Yu, Z. T., Chen, C., Kling, D. E., Liu, B., McCoy, J. M., Merighi, M., … Newburg, D. S. (2013). The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology, 23(2), 169–177. https://doi.org/10.1093/glycob/cws138 

4. Ashida, H., Miyake, A., Kiyohara, M., Wada, J., Yoshida, E., Kumagai, H., … Yamamoto, K. (2009). Two distinct α-L-fucosidases from Bifidobacterium bifidum are essential for the utilization of fucosylated milk oligosaccharides and glycoconjugates. Glycobiology, 19(9), 1010–1017. https://doi.org/10.1093/glycob/cwp082 

5. Schwab, C., & Gänzle, M. (2011). Lactic acid bacteria fermentation of human milk oligosaccharide components, human milk oligosaccharides and galactooligosaccharides. FEMS Microbiology Letters, 315(2), 141–148. https://doi.org/10.1111/j.1574-6968.2010.02185.x

HMO Health Benefit Solutions

Human Milk Oligosaccharides may support a number of health benefits such as immunity and gut health in early life.

More than ingredients

Learn how DSM can help your business. Select the options below to connect your needs with the right solution.

I'd like to explore...

If the options above don't sound like you, skip ahead and contact us.

Quick Links

Food Specialties

Discover enzymes for baking, brewing, dairy and more.

Health Benefit Solutions

Solutions to address consumers' health and lifestyle needs.

Scientific Services

Science-based expertise supporting innovations that meet consumer needs.

About DSM

Our purpose is to create brighter lives for all.

Talking Nutrition

Explore new science, consumer insights, industry events and more.

Webshop

Request samples, place orders and view product documentation.

This website uses cookies. We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.

Learn more